TNFRSF10B and pancreatic neoplasm: A DR5 targeting ADC (Oba01) has recently shown promising pre-clinical anti-tumor activity both as a monotherapy and in combination with gemcitabine in cell-line derived and patient-derived pancreatic cancer xenograft models [59].